Trevor E Angell1, Mary C Frates1, Marco Medici1, Xiaoyun Liu1, Norra Kwong1, Edmund S Cibas1, Matthew I Kim1, Ellen Marqusee1. 1. Thyroid Section (T.E.A., M.M., X.L., N.K., M.I.K., E.M.), Division of Endocrinology, Hypertension, and Diabetes, and Departments of Radiology (M.C.F.) and Pathology (E.S.C.), Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115; Rotterdam Thyroid Center and Department of Internal Medicine (M.M.), Erasmus University Medical Center, 3000 DR Rotterdam, The Netherlands; and Department of Endocrinology (X.L.), First Affiliated Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu Province, China.
Abstract
CONTEXT: The Afirma gene expression classifier (GEC) is a molecular diagnostic test that has a high negative predictive value for ruling out malignancy in thyroid nodules with indeterminate cytology. Many patients with a cytologically indeterminate and GEC benign (Cyto-I/GEC-B) nodule undergo monitoring instead of diagnostic surgery, but few data describe their follow-up. OBJECTIVE: The objective of the study was to determine the sonographic changes and clinical outcomes for patients with Cyto-I/GEC-B nodules compared with patients with cytologically benign (Cyto-B) nodules. DESIGN: This was a retrospective analysis of consecutive Cyto-I/GEC-B nodules evaluated at Brigham and Women's Hospital compared with Cyto-B nodules. MAIN OUTCOMES: Nodule growth of 20% or greater in two dimensions or of 50% or greater in volume, change in sonographic features, and rates of repeat fine-needle aspiration, thyroidectomy, and malignancy. RESULTS: Ninety-five Cyto-I/GEC-B nodules in 90 patients were identified. Five patients underwent primary surgical resection. Of the remaining 90 nodules, 58 (64.4%) had sonographic follow-up available at a median of 13 months (range 4-40 mo). Cyto-I/GEC-B nodules showed similar growth compared with 1224 Cyto-B nodules using either of the following criteria: 20% or greater in two dimensions (8.6% vs 8.3%, P = .80) or 50% or greater in volume (17.2% vs 13.8%, P = .44). Thyroidectomies were more frequent in the Cyto-I/GEC-B group (13.8% vs 0.9%, P < .0001), but cancer was found in only one patient, with no evidence of persistent disease after initial treatment. CONCLUSIONS: Cyto-I/GEC-B nodules demonstrate similar growth to Cyto-B nodules during follow-up. Although Cyto-I/GEC-B nodules were more frequently resected, only one malignancy was found. These data suggest that reassessment of Cyto-I/GEC-B nodules may be performed similarly to those with benign cytology.
CONTEXT: The Afirma gene expression classifier (GEC) is a molecular diagnostic test that has a high negative predictive value for ruling out malignancy in thyroid nodules with indeterminate cytology. Many patients with a cytologically indeterminate and GEC benign (Cyto-I/GEC-B) nodule undergo monitoring instead of diagnostic surgery, but few data describe their follow-up. OBJECTIVE: The objective of the study was to determine the sonographic changes and clinical outcomes for patients with Cyto-I/GEC-B nodules compared with patients with cytologically benign (Cyto-B) nodules. DESIGN: This was a retrospective analysis of consecutive Cyto-I/GEC-B nodules evaluated at Brigham and Women's Hospital compared with Cyto-B nodules. MAIN OUTCOMES: Nodule growth of 20% or greater in two dimensions or of 50% or greater in volume, change in sonographic features, and rates of repeat fine-needle aspiration, thyroidectomy, and malignancy. RESULTS: Ninety-five Cyto-I/GEC-B nodules in 90 patients were identified. Five patients underwent primary surgical resection. Of the remaining 90 nodules, 58 (64.4%) had sonographic follow-up available at a median of 13 months (range 4-40 mo). Cyto-I/GEC-B nodules showed similar growth compared with 1224 Cyto-B nodules using either of the following criteria: 20% or greater in two dimensions (8.6% vs 8.3%, P = .80) or 50% or greater in volume (17.2% vs 13.8%, P = .44). Thyroidectomies were more frequent in the Cyto-I/GEC-B group (13.8% vs 0.9%, P < .0001), but cancer was found in only one patient, with no evidence of persistent disease after initial treatment. CONCLUSIONS: Cyto-I/GEC-B nodules demonstrate similar growth to Cyto-B nodules during follow-up. Although Cyto-I/GEC-B nodules were more frequently resected, only one malignancy was found. These data suggest that reassessment of Cyto-I/GEC-B nodules may be performed similarly to those with benign cytology.
Authors: A Bergenfelz; S Jansson; A Kristoffersson; H Mårtensson; E Reihnér; G Wallin; I Lausen Journal: Langenbecks Arch Surg Date: 2008-07-17 Impact factor: 3.445
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: Erik K Alexander; Giulia C Kennedy; Zubair W Baloch; Edmund S Cibas; Darya Chudova; James Diggans; Lyssa Friedman; Richard T Kloos; Virginia A LiVolsi; Susan J Mandel; Stephen S Raab; Juan Rosai; David L Steward; P Sean Walsh; Jonathan I Wilde; Martha A Zeiger; Richard B Lanman; Bryan R Haugen Journal: N Engl J Med Date: 2012-06-25 Impact factor: 91.245
Authors: Sophia C Kamran; Ellen Marqusee; Mathew I Kim; Mary C Frates; Julie Ritner; Hope Peters; Carol B Benson; Peter M Doubilet; Edmund S Cibas; Justine Barletta; Nancy Cho; Atul Gawande; Daniel Ruan; Francis D Moore; Karla Pou; P Reed Larsen; Erik K Alexander Journal: J Clin Endocrinol Metab Date: 2012-12-28 Impact factor: 5.958
Authors: Eran Brauner; Brittany J Holmes; Jeffrey F Krane; Michiya Nishino; David Zurakowski; James V Hennessey; William C Faquin; Sareh Parangi Journal: Thyroid Date: 2015-06-04 Impact factor: 6.568
Authors: Eric Nou; Norra Kwong; Lukas K Alexander; Edmund S Cibas; Ellen Marqusee; Erik K Alexander Journal: J Clin Endocrinol Metab Date: 2013-11-25 Impact factor: 5.958
Authors: Juan P Brito; Michael R Gionfriddo; Alaa Al Nofal; Kasey R Boehmer; Aaron L Leppin; Carl Reading; Matthew Callstrom; Tarig A Elraiyah; Larry J Prokop; Marius N Stan; M Hassan Murad; John C Morris; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2013-11-25 Impact factor: 5.958
Authors: Mayumi Endo; Fadi Nabhan; Kyle Porter; Katie Roll; Lawrence A Shirley; Irina Azaryan; Dena Tonkovich; Jeanette Perlick; Laura E Ryan; Raheela Khawaja; Shumei Meng; John E Phay; Matthew D Ringel; Jennifer A Sipos Journal: Thyroid Date: 2019-07-17 Impact factor: 6.568
Authors: Mayumi Endo; Kyle Porter; Clarine Long; Irina Azaryan; John E Phay; Matthew D Ringel; Jennifer A Sipos; Fadi Nabhan Journal: J Clin Endocrinol Metab Date: 2020-11-01 Impact factor: 5.958
Authors: Sergio Vargas-Salas; José R Martínez; Soledad Urra; José Miguel Domínguez; Natalia Mena; Thomas Uslar; Marcela Lagos; Marcela Henríquez; Hernán E González Journal: Endocr Relat Cancer Date: 2017-12-18 Impact factor: 5.678
Authors: Ghobad Azizi; James M Keller; Michelle L Mayo; Kelé Piper; David Puett; Karly M Earp; Carl D Malchoff Journal: Endocrine Date: 2018-01-19 Impact factor: 3.633
Authors: Sylvan C Baca; Kristine S Wong; Kyle C Strickland; Howard T Heller; Matthew I Kim; Justine A Barletta; Edmund S Cibas; Jeffrey F Krane; Ellen Marqusee; Trevor E Angell Journal: Cancer Cytopathol Date: 2017-02-02 Impact factor: 5.284
Authors: Moraima Pagan; Richard T Kloos; Chu-Fang Lin; Kevin J Travers; Hajime Matsuzaki; Ed Y Tom; Su Yeon Kim; Mei G Wong; Andrew C Stewart; Jing Huang; P Sean Walsh; Robert J Monroe; Giulia C Kennedy Journal: BMC Bioinformatics Date: 2016-01-11 Impact factor: 3.169
Authors: Zeyad T Sahli; Philip W Smith; Christopher B Umbricht; Martha A Zeiger Journal: Front Endocrinol (Lausanne) Date: 2018-04-18 Impact factor: 5.555